Effect of quercetin and desferrioxamine on 6-hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats

Journal of Toxicological Sciences

Volumn 38, Issue 1, 2013, Pages 25-33

  Haleagrahara, Nagaraja ^a   Siew, Cheng Jun ^b   Ponnusamy, Kumar ^c  

^a JAMES COOK UNIVERSITY   (Australia)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^c AIMST UNIVERSITY   (Malaysia)

Author keywords

6 hydroxydopamine; Antioxidants; Dopamine; Neuroprotection; Neurotoxocity

Indexed keywords

CARBONYL DERIVATIVE; DEFEROXAMINE; DOPAMINE; GLUTATHIONE; OXIDOPAMINE; QUERCETIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BIOCHEMISTRY; BODY WEIGHT; CHEMICAL ANALYSIS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD INTAKE; HISTOLOGY; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; RAT; SPECTROPHOTOMETRY;

EID: 84873208623     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.38.25     Document Type: Article

References (25)

1. Andringa, G., van Oosten, R.V., Unger, W., Hafmans, T.G., Veening, J., Stoof, J.C. and Cools, A.R. (2000): Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamineinduced lesions in the substantia nigra. Eur. J. Neurosci., 12, 3033-3043.
2. Ben-Shachar, D., Eshel, G., Finberg, J.P. and Youdim, M.B. (1991): The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine- induced degeneration of nigrostriatal dopamine neurons. J. Neurochem., 56, 1441-1444.
3. Blum, D., Torch, S., Lambeng, N., Nissou, M., Benabid, A.L., Sadoul, R. and Verna, J.M. (2001): Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol., 65, 135-172.
4. Breese, G.R. and Traylor, T.D. (1971): Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br. J. Pharmacol., 42, 88-99.
5. Cannon, J.R. and Greenamyre, J.T. (2010): Neurotoxic in vivo models of Parkinson's disease recent advances. Prog. Brain Res., 184, 17-33.
6. Cicchetti, F., Drouin-Ouellet, J. and Gross, R.E. (2009): Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models? Trends Pharmacol. Sci., 30, 475-483.
7. David, V., Katerina, V., Ana, R.M., Catarina, R. and Jeremy, P.E.S. (2008): The neuroprotective potential of flavonoids: a multiplicity of effects. Genes Nutr., 3, 115-126.
8. Deumens, R., Blokland, A. and Prickaerts, J. (2002): Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol., 175, 303-317.
9. Ellenbroek, B.A., Peeters, B.W., Honig, W.M. and Cools, A.R. (1987): The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology, 93, 343-348.
10. Glinka, Y., Tipton, K.F. and Youdim, M.B. (1998): Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. Eur. J. Pharmacol., 351, 121-129.
11. Grunblatt, E., Mandel, S., Gassen, M., Youdim, M.B. (1999): Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. J. Neural. Transm. Suppl., 55, 57-70.
12. Guelman, L.R., Pagotto, R.M.L., Di Toro, C.G. and Zieher, L.M. (2004): Deferoxamine antioxidant activity on cerebellar granule cells γ-irradiated in vitro. Neurotoxicol. Teratol., 26, 477-483.
13. He, Y., Lee, T. and Leong, S.K. (2000): 6-Hydroxydopamine induced apoptosis of dopaminergic cells in the rat substantia nigra. Brain Res., 858, 163-166.
14. Lan, J. and Jiang, D.H. (1997): Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Transm., 104, 469-481.
15. Laursen, H. and Diemer, N.H. (1979): Morphometric studies of rat glial cell ultrastructure after urease-induced hyperammonaemia. Neuropathol. Appl. Neurobiol., 5, 345-362.
16. Loke, W.M., Proudfoot, J.M., McKinley, A.J., Needs, P.W., Kroon, P.A., Hodgson, J.M. and Croft, K.D. (2008): Quercetin and its in vivo metabolites inhibit neutrophil-mediated low-density lipoprotein oxidation. J. Agric. Food Chem., 56, 3609-3615.
17. Miean, K.H. and Mohamed, S. (2001): Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J. Agric. Food Chem., 49, 3106-3112.
18. Nakamura, T., Keep, R.F., Hua, Y., Schallert, T., Hoff, J.T. and Xi, G. (2004): Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. J. Neurosurg., 100, 672-678.
19. Okauchi, M., Hua, Y., Keep, R.F., Morgenstern, L.B. and Xi, G. (2009): Effects of deferoxamine on intracerebral hemorrhageinduced brain injury in aged rats. Stroke, 40, 1858-1863.
20. Reiter, R.J. (1998): Oxidative damage in the central nervous sys- tem: protection by melatonin. Prog. Neurobiol., 56, 359-384.
21. Singh, A., Naidu, P.S. and Kulkarni, S.K. (2003): Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition. Pharmacology, 68, 81-88.
22. Storch, A., Storch, M., Collins, M.A (2001): Dopaminergic Neurodegeneration. In: Storch, A and Schwarz J, editors. Neurotoxic Factors in Parkinson's disease and Related Disorders. 1st ed. ULM: Springer.
23. Truong, L., Allbutt, H., Kassiou, M. and Henderson, J.M. (2006): Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Behav. Brain Res., 169, 1-9.
24. Uversky, V.N. (2004): Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res., 318, 225-241.
25. Yuan, W.J., Yasuhara, T., Shingo, T., Muraoka, K., Agari, T., Kameda, M., Uozumi, T., Tajiri, N., Morimoto, T., Jing, M., Baba, T., Wang, F., Leung, H., Matsui, T., Miyoshi, Y. and Date, I. (2008): Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. BMC Neurosci., 9, 75.